Particulates in your ATMP – Now What?! Methods & Strategies to rescue timelines and improve formulations
Particulates remain one of the most common and costly challenges in pharmaceutical manufacturing. Identifying the root cause of these particulates is essential to de-risk clinical development and ensure product quality. This challenge is particularly significant for advanced therapeutics such as viral vectors and cell therapies, where limited batch sizes make traditional particulate analysis difficult, as these methods often require large sample volumes.
Join Philipp Beck, Ph.D., from Ascend Advanced Therapies as he discusses stability study strategies and compares modern particulate analysis technologies. The webinar will also highlight the advantages of Backgrounded Membrane Imaging and explain why Waters Aura is a must-have platform for formulation development.
Speaker: Philipp Beck, PhD (Manager Formulation Development, Ascend Advance Therapies)
Speaker: Paul Dyer, PhD (Principal Market Application Specialist (Aura), Waters Corporation
